Russia is planning a very extensive approach to track and trace, which will go far beyond what is planning in Europe. Process worldwide talks with software specialist Dr. Stefan Oing, head of track & trace software at Atlantic Zeiser, about what that means.
Russia is planning a full serialization and track & trace system from the pharmaceutical manufacturers to the end users with extra functionality. In February 2017 the government started a pilot project involving a number of companies across the supply chain. Aim is to test a track & trace system.
? Mr. Oing, please tell us, what is being planned in Russia?
Stefan Oing: An extremely extensive approach is to be implemented in Russia. It will go far beyond what is planned in the EU and even overshadow Brazil’s original intentions, which are still being fulfilled.
? Can you explain the approach in more detail?
Oing: The Russian concept, codenamed FSIS DCM, is focused on capturing the path traced by a drug all the way from its manufacturer to the end user.
? That sounds very much like the track and trace policies that are envisaged in other markets.
Oing: Two things distinguish Russia from other markets, the first of which is the abundance of data that is to be captured. Second — and this is a key point — the difference lies in the express goals of being able both to evaluate the data according to various criteria and to make it available again to the market players according to certain criteria. Fundamentally, Russia’s approach envisages intensive monitoring and evaluation of the entire pharmaceuticals market. Its primary intention, of course, is to prevent counterfeit pharmaceuticals from entering the logistics and supply chain.
This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 44762387 / Pharma & Food)